Recommended Business Combination of Redx Pharma PLC and Jounce Therapeutics, Inc.

RECOMMENDED BUSINESS COMBINATION OF REDX PHARMA PLC AND JOUNCE THERAPEUTICS, INC. (“Business Combination”)

In this microsite you’ll find information about the Business Combination of Redx Pharma PLC and Jounce Therapeutics, Inc.

 

SECTION TITLE DOCUMENT DESCRIPTION
   
Rule 2.7 Announcement Rule 2.7 Announcement
Rule 2.11 Letter Rule 2.11 Letter to Jounce employees
Offer- related Agreements Cooperation Agreement
  Merger Agreement
  Joint Defense Agreement
  Confidentiality Agreement
 
Consent Letters in relation to Rule 2.7 Announcement FTI Consulting (PR Advisor to Redx)
  Centerview Partners UK LLP (Financial Adviser to Redx)
  SPARK Advisory Partners Limited (Nominated Adviser to Redx)
  WG Partners LLP
  Cowen Execution Services Limited (Financial Adviser to Jounce)
 
Redx Pharma PLC Directors’ Irrevocable Undertakings to support the Business Combination Dr Jane Griffiths

Lisa Anson

Peter Presland

Sarah Wild

Dr Bernhard Kirschbaum

Dr Robert Scott
 
Redx Pharma PLC Shareholders’ Irrevocable Undertakings to support the Business Combination RM Special Holdings 3, LLC
  RedCo II Master Fund, L.P.
  Sofinnova Crossover I SLP
  Polar Capital Funds Plc for and on behalf of Polar Capital Funds PLC- Healthcare Opportunities Funds
 
Voting and Support Agreements Elizabeth Trehu

Luisa Salter-Cid

Jigar Raythatha

Richard Murray

Perry Karsen

Robert Kamen

Robert Iannone

Barbara Duncan

Luis Diaz

Hugh Cole

Kim Drapkin

Gilead Sciences, Inc.

RTW Venture Fund Limited
   
Other Documents Letter Agreement
  Registration Rights Agreement
  2.7 Announcement Presentation
Form 8 of Jounce Therapeutics, Inc.

Press Release of Jounce Therapeutics, Inc. dated March 14, 2023